首页 > 最新文献

Cancer Nanotechnology最新文献

英文 中文
Retraction Note: Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts 撤稿说明:绿色合成负载硫醇化壳聚糖的溶瘤新城疫病毒纳米制剂,用于在宫颈癌异种移植物中靶向递送和持续释放病毒
IF 5.7 2区 工程技术 Q2 NANOSCIENCE & NANOTECHNOLOGY Pub Date : 2024-07-30 DOI: 10.1186/s12645-024-00279-x
Kousain Kousar, Faiza Naseer, Maisa S. Abduh, Sadia Anjum, Tahir Ahmad

Retraction: Cancer Nanotechnology (2023) 14:71 https://doi.org/10.1186/s12645-023-00220-8

The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding overlapping images in the presented data. Specifically:

Multiple images in Fig. 8a appear highly similar to those in Fig. 17 in Naseer et al. (2023), representing different groups.

Multiple images in Fig. 8b appear highly similar to those in Fig. 18 in Naseer et al. (2023), representing different groups.

  • Fig. 8a D1 appears highly similar to Fig. 8b D3.

  • Fig. 8a E1 and E2 appear to overlap with different magnification.

  • Fig. 9a A5 insert (low magnification image) appears highly similar to that in B5.

  • Fig. 9a A9 and b D7 appear to overlap with different contrast.

  • Fig. 9a A10, A12 and B10 appear to overlap.

  • Fig. 9a B1 and b C1, C3 appear to overlap with different magnification.

  • Fig. 9a B3 and b C2, D2 appear to overlap with different magnification and contrast.

  • Fig. 9a B4 and b D4 appear to overlap.

  • Fig. 9a B10 and B11 appear to overlap.

Additionally, the rat body weight data presented in Fig. 5a (~ 160 g at week 1) appear to be contrary to the description in the Methods (200–250 g).

The Editors-in-Chief therefore no longer have confidence in the presented data.

None of the authors have responded to any correspondence from the editor or publisher about this retraction notice.

  • Naseer F, Kousar K, Abduh MS et al (2023) Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation. Cancer Nanotechnol 14:65. https://doi.org/10.1186/s12645-023-00218-2

    Article CAS Google Scholar

Download references

Authors and Affiliations

  1. Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan

    Kousain Kousar, Faiza Naseer & Tahir Ahmad

  2. Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan

    Faiza Naseer

  3. Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdul-Aziz University, 21589, Jeddah, Saudi Arabia

    Maisa S. Abduh

  4. Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia

    Maisa S. Abduh

  5. <
撤稿:Cancer Nanotechnology (2023) 14:71 https://doi.org/10.1186/s12645-023-00220-8The 主编已撤回这篇文章。文章发表后,有人对文中数据中的重叠图像提出了质疑。具体来说:图 8a 中的多幅图像与 Naseer 等人(2023 年)的图 17 中的图像高度相似,代表不同的组别。图 8b 中的多幅图像与 Naseer 等人(2023 年)的图 18 中的图像高度相似,代表不同的组别。图 9a A5 插页(低放大率图像)与 B5 中的插页高度相似。图 9a A9 和 b D7 以不同的对比度出现重叠。此外,图 5a 中显示的大鼠体重数据(第 1 周时约为 160 克)似乎与《方法》中的描述(200-250 克)相反。Naseer F, Kousar K, Abduh MS et al (2023) Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation.Cancer Nanotechnol 14:65. https://doi.org/10.1186/s12645-023-00218-2Article CAS Google Scholar Download references作者及工作单位巴基斯坦伊斯兰堡国立科技大学阿塔-乌尔-拉赫曼应用生物科学学院工业生物技术Kousain Kousar, Faiza Naseer &;Tahir Ahmad巴基斯坦伊斯兰堡希法塔梅尔-伊-米拉特大学希法制药科学学院法伊扎-纳西尔沙特阿拉伯吉达 21589 阿卜杜勒-阿齐兹国王大学应用医学系医学实验室科学系不同疾病中的免疫反应研究小组麦萨-S.AbduhCenter of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi ArabiaMaisa S. AbduhDepartment of Biology, University of Hail, Hail, Saudi ArabiaSadia AnjumAuthorsKousain KousarView author publications您也可以在PubMed Google Scholar中搜索该作者Faiza NaseerView author publications您也可以在PubMed Google Scholar中搜索该作者Maisa S. Abduh查看作者发表的论文Abduh查看作者发表的文章您也可以在PubMed Google Scholar中搜索该作者Sadia Anjum查看作者发表的文章您也可以在PubMed Google Scholar中搜索该作者Tahir Ahmad查看作者发表的文章您也可以在PubMed Google Scholar中搜索该作者通信作者Kousain Kousar或Tahir Ahmad.Publisher's NoteSpringer Nature对出版地图和机构隶属关系中的管辖权主张保持中立。开放获取 本文采用知识共享署名 4.0 国际许可协议,该协议允许以任何媒介或格式使用、共享、改编、分发和复制本文,但必须注明原作者和出处,提供知识共享许可协议的链接,并说明是否进行了修改。本文中的图片或其他第三方材料均包含在文章的知识共享许可协议中,除非在材料的署名栏中另有说明。如果材料未包含在文章的知识共享许可协议中,且您打算使用的材料不符合法律规定或超出许可使用范围,您需要直接从版权所有者处获得许可。如需查看该许可的副本,请访问 http://creativecommons.org/licenses/by/4.0/。创意共享公共领域专用免责声明(http://creativecommons.org/publicdomain/zero/1.0/)适用于本文提供的数据,除非在数据的信用行中另有说明。 引用本文Kousar, K., Naseer, F., Abduh, M.S. et al. Retraction Note: Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts.Cancer Nano 15, 40 (2024). https://doi.org/10.1186/s12645-024-00279-xDownload citationPublished: 30 July 2024DOI: https://doi.org/10.1186/s12645-024-00279-xShare this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative.
{"title":"Retraction Note: Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts","authors":"Kousain Kousar, Faiza Naseer, Maisa S. Abduh, Sadia Anjum, Tahir Ahmad","doi":"10.1186/s12645-024-00279-x","DOIUrl":"https://doi.org/10.1186/s12645-024-00279-x","url":null,"abstract":"<p><b>Retraction</b><b>: </b><b>Cancer Nanotechnology (2023) 14:71 </b><b>https://doi.org/10.1186/s12645-023-00220-8</b></p><p>The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding overlapping images in the presented data. Specifically:</p><p>Multiple images in Fig. 8a appear highly similar to those in Fig. 17 in Naseer et al. (2023), representing different groups.</p><p>Multiple images in Fig. 8b appear highly similar to those in Fig. 18 in Naseer et al. (2023), representing different groups.</p><ul>\u0000<li>\u0000<p>Fig. 8a D1 appears highly similar to Fig. 8b D3.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 8a E1 and E2 appear to overlap with different magnification.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a A5 insert (low magnification image) appears highly similar to that in B5.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a A9 and b D7 appear to overlap with different contrast.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a A10, A12 and B10 appear to overlap.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a B1 and b C1, C3 appear to overlap with different magnification.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a B3 and b C2, D2 appear to overlap with different magnification and contrast.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a B4 and b D4 appear to overlap.</p>\u0000</li>\u0000<li>\u0000<p>Fig. 9a B10 and B11 appear to overlap.</p>\u0000</li>\u0000</ul><p>Additionally, the rat body weight data presented in Fig. 5a (~ 160 g at week 1) appear to be contrary to the description in the Methods (200–250 g).</p><p>The Editors-in-Chief therefore no longer have confidence in the presented data.</p><p>None of the authors have responded to any correspondence from the editor or publisher about this retraction notice.</p><ul data-track-component=\"outbound reference\" data-track-context=\"references section\"><li><p>Naseer F, Kousar K, Abduh MS et al (2023) Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation. Cancer Nanotechnol 14:65. https://doi.org/10.1186/s12645-023-00218-2</p><p>Article CAS Google Scholar </p></li></ul><p>Download references<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><h3>Authors and Affiliations</h3><ol><li><p>Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan</p><p>Kousain Kousar, Faiza Naseer &amp; Tahir Ahmad</p></li><li><p>Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan</p><p>Faiza Naseer</p></li><li><p>Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdul-Aziz University, 21589, Jeddah, Saudi Arabia</p><p>Maisa S. Abduh</p></li><li><p>Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia</p><p>Maisa S. Abduh</p></li><","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141867552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction Note: Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation 撤稿说明:CD44靶向长春新碱纳米制剂在前列腺癌异种移植模型中的抗癌潜力评估:一种用于高级药代动力学评估的多动力方法
IF 5.7 2区 工程技术 Q2 NANOSCIENCE & NANOTECHNOLOGY Pub Date : 2024-07-27 DOI: 10.1186/s12645-024-00278-y
Faiza Naseer, Kousain Kousar, Maisa S. Abduh, Sadia Anjum, Tahir Ahmad

Retraction Note: Cancer Nanotechnology (2023) 14:65 https://doi.org/10.1186/s12645-023-00218-2


The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding some of the images presented in the figures, specifically:

  • Fig. 6 appears highly similar to Fig. 10 of Naseer et al. (2023)

  • Fig. 6 Pure VC 12 h 90 ug/ml and VC-loaded TCs-HA 24 h 50 ug/ml images appear highly similar

  • Fig. 17 A5 and Fig. 18 D5 images appear to overlap (flipped and with different magnification)

  • Fig. 18 C6 and D6 appear to overlap (with different magnification)

  • Several panels in Figs. 17 and 18 appear highly similar to those in Fig. 8 of Kousar et al. (2023)

The authors have been unable to provide the underlying raw data upon request. The Editors-in-Chief therefore no longer have confidence in the presented data.

None of the authors have responded to any correspondence from the editor or publisher about this retraction notice.

  • Naseer F, Ahmad T, Kousar K, Kakar S, Gul R, Anjum S, Shareef U (2023) Formulation for the targeted delivery of a vaccine strain of oncolytic measles virus (OMV) in hyaluronic acid coated thiolated chitosan as a green nanoformulation for the treatment of prostate cancer: a viro-immunotherapeutic approach. Int J Nanomed 18:185–205. https://doi.org/10.2147/IJN.S386560

    Article CAS Google Scholar

  • Kousar K, Naseer F, Abduh MS et al (2023) Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts. Cancer Nano 14:71. https://doi.org/10.1186/s12645-023-00220-8

    Article CAS Google Scholar

Download references

Authors and Affiliations

  1. Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan

    Faiza Naseer, Kousain Kousar & Tahir Ahmad

  2. Shifa College of Pharmaceutical Sciences, Shifa Tameer e Millat University, Islamabad, Pakistan

    Faiza Naseer

  3. Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdul-Aziz University, 21589, Jeddah, Saudi Arabia

    Maisa S. Abduh

  4. Department of Biology, University of Hail, Hail, Saudi Arabia

    Sadia Anjum

Authors
  1. Faiza NaseerView author publications

    You can also search for this author in PubMed Google Sch

撤稿说明:Cancer Nanotechnology (2023) 14:65 https://doi.org/10.1186/s12645-023-00218-2The 主编已撤回这篇文章。图 6 纯 VC 12 h 90 ug/ml 和 VC-loaded TCs-HA 24 h 50 ug/ml 的图像高度相似。图 17 A5 和图 18 D5 的图像出现重叠(翻转且放大倍数不同)。图 17 和 18 中的几个面板与 Kousar 等人(2023 年)的图 8 中的面板高度相似。因此,主编对所提供的数据不再有信心。作者均未回复编辑或出版商有关撤稿通知的任何信件。Naseer F, Ahmad T, Kousar K, Kakar S, Gul R, Anjum S, Shareef U (2023) 在透明质酸包覆的硫醇化壳聚糖中靶向递送溶瘤麻疹病毒(OMV)疫苗株的制剂,作为治疗前列腺癌的绿色纳米制剂:一种病毒免疫治疗方法。https://doi.org/10.2147/IJN.S386560Article CAS Google Scholar Kousar K, Naseer F, Abduh MS et al (2023) Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts.Cancer Nano 14:71. https://doi.org/10.1186/s12645-023-00220-8Article CAS Google Scholar Download references作者和工作单位巴基斯坦伊斯兰堡国立科技大学阿塔-乌尔-拉赫曼应用生物科学学院工业生物技术Faiza Naseer, Kousain Kousar &;Tahir Ahmad巴基斯坦伊斯兰堡希法 Tameer e Millat 大学希法制药科学学院Faiza Naseer沙特阿拉伯吉达 21589 阿卜杜勒-阿齐兹国王大学应用医学科学院医学实验室科学系不同疾病中的免疫反应研究小组Maisa S. AbduhDepartment of Biology, Kousain Kousar &.AbduhDepartment of Biology, University of Hail, Hail, Saudi ArabiaSadia AnjumAuthorsFaiza NaseerView author publications您也可以在PubMed Google Scholar中搜索该作者Kousain KousarView author publications您也可以在PubMed Google Scholar中搜索该作者Maisa S. Abduh查看作者发表的文章Abduh查看作者发表的文章您也可以在PubMed Google Scholar中搜索该作者Sadia Anjum查看作者发表的文章您也可以在PubMed Google Scholar中搜索该作者Tahir Ahmad查看作者发表的文章您也可以在PubMed Google Scholar中搜索该作者通信作者通信作者:Faiza Naseer或Tahir Ahmad.Publisher's NoteSpringer Nature对出版地图和机构隶属关系中的管辖权主张保持中立。开放获取 本文采用知识共享署名 4.0 国际许可协议,该协议允许以任何媒介或格式使用、共享、改编、分发和复制本文,但必须注明原作者和出处,提供知识共享许可协议的链接,并说明是否进行了修改。本文中的图片或其他第三方材料均包含在文章的知识共享许可协议中,除非在材料的署名栏中另有说明。如果材料未包含在文章的知识共享许可协议中,且您打算使用的材料不符合法律规定或超出许可使用范围,则您需要直接从版权所有者处获得许可。要查看该许可的副本,请访问 http://creativecommons.org/licenses/by/4.0/。除非在数据的信用行中另有说明,否则创作共用公共领域专用免责声明 (http://creativecommons.org/publicdomain/zero/1.0/) 适用于本文提供的数据。引用本文Naseer, F., Kousar, K., Abduh, M.S. et al. Retraction Note: Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation.Cancer Nano 15, 39 (2024). https://doi.org/10.1186/s12645-024-00278-yDownload citationPublished: 27 July 2024DOI: https://doi.org/10.1186/s12645-024-00278-yShare this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative
{"title":"Retraction Note: Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation","authors":"Faiza Naseer, Kousain Kousar, Maisa S. Abduh, Sadia Anjum, Tahir Ahmad","doi":"10.1186/s12645-024-00278-y","DOIUrl":"https://doi.org/10.1186/s12645-024-00278-y","url":null,"abstract":"<br/><p><b>Retraction Note: Cancer Nanotechnology (2023) 14:65</b> <b>https://doi.org/10.1186/s12645-023-00218-2</b></p><br/><p>The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding some of the images presented in the figures, specifically:</p><ul>\u0000<li>\u0000<p>Fig. 6 appears highly similar to Fig. 10 of Naseer et al. (2023)</p>\u0000</li>\u0000<li>\u0000<p>Fig. 6 Pure VC 12 h 90 ug/ml and VC-loaded TCs-HA 24 h 50 ug/ml images appear highly similar</p>\u0000</li>\u0000<li>\u0000<p>Fig. 17 A5 and Fig. 18 D5 images appear to overlap (flipped and with different magnification)</p>\u0000</li>\u0000<li>\u0000<p>Fig. 18 C6 and D6 appear to overlap (with different magnification)</p>\u0000</li>\u0000<li>\u0000<p>Several panels in Figs. 17 and 18 appear highly similar to those in Fig. 8 of Kousar et al. (2023)</p>\u0000</li>\u0000</ul><p>The authors have been unable to provide the underlying raw data upon request. The Editors-in-Chief therefore no longer have confidence in the presented data.</p><p>None of the authors have responded to any correspondence from the editor or publisher about this retraction notice.</p><ul data-track-component=\"outbound reference\" data-track-context=\"references section\"><li><p>Naseer F, Ahmad T, Kousar K, Kakar S, Gul R, Anjum S, Shareef U (2023) Formulation for the targeted delivery of a vaccine strain of oncolytic measles virus (OMV) in hyaluronic acid coated thiolated chitosan as a green nanoformulation for the treatment of prostate cancer: a viro-immunotherapeutic approach. Int J Nanomed 18:185–205. https://doi.org/10.2147/IJN.S386560</p><p>Article CAS Google Scholar </p></li><li><p>Kousar K, Naseer F, Abduh MS et al (2023) Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts. Cancer Nano 14:71. https://doi.org/10.1186/s12645-023-00220-8</p><p>Article CAS Google Scholar </p></li></ul><p>Download references<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><h3>Authors and Affiliations</h3><ol><li><p>Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan</p><p>Faiza Naseer, Kousain Kousar &amp; Tahir Ahmad</p></li><li><p>Shifa College of Pharmaceutical Sciences, Shifa Tameer e Millat University, Islamabad, Pakistan</p><p>Faiza Naseer</p></li><li><p>Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdul-Aziz University, 21589, Jeddah, Saudi Arabia</p><p>Maisa S. Abduh</p></li><li><p>Department of Biology, University of Hail, Hail, Saudi Arabia</p><p>Sadia Anjum</p></li></ol><span>Authors</span><ol><li><span>Faiza Naseer</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Sch","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141772924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Studies on the thermal sensitivity of lung cancer cells exposed to an alternating magnetic field and magnesium-doped maghemite nanoparticles 暴露于交变磁场和掺镁氧化镁纳米粒子的肺癌细胞的热敏感性研究
IF 5.7 2区 工程技术 Q2 NANOSCIENCE & NANOTECHNOLOGY Pub Date : 2024-07-22 DOI: 10.1186/s12645-024-00276-0
Malgorzata Sikorska, Grzegorz Domanski, Magdalena Bamburowicz-Klimkowska, Artur Kasprzak, Anna M. Nowicka, Monika Ruzycka-Ayoush, Ireneusz P. Grudzinski
Magnetic fluid hyperthermia (MFH) represents a promising therapeutic strategy in cancer utilizing the heating capabilities of magnetic nanoparticles when exposed to an alternating magnetic field (AMF). Because the efficacy and safety of MFH treatments depends on numerous intrinsic and extrinsic factors, therefore, the proper MFH setups should focus on thermal energy dosed into the cancer cells. In this study, we performed MFH experiments using human lung cancer A549 cells (in vitro) and NUDE Balb/c mice bearing human lung (A549) cancer (in vivo). In these two experimental models, the heat was induced by magnesium-doped iron(III) oxide nanoparticles coated with mPEG-silane (Mg0.1-γ-Fe2O3(mPEG-silane)0.5) when exposed to an AMF. We observed that the lung cancer cells treated with Mg0.1-γ-Fe2O3(mPEG-silane)0.5 (0.25 mg·mL−1) and magnetized for 30 min at 14.4 kA·m−1 yielded a satisfactory outcome in reducing the cell viability up to ca. 21% (in vitro). The activation energy calculated for this field strength was estimated for 349 kJ·mol−1. Both volumetric measurements and tumor mass assessments confirmed by magnetic resonance imaging (MRI) showed a superior thermal effect in mice bearing human lung cancer injected intratumorally with Mg0.1-γ-Fe2O3(mPEG-silane)0.5 nanoparticles (3 mg·mL−1) and subjected to an AMF (18.3 kA·m−1) for 30 min four times at weekly intervals. Research demonstrated that mice undergoing MFH exhibited a marked suppression of tumor growth (V = 169 ± 94 mm3; p < 0.05) in comparison to the control group of untreated mice. The CEM43 (cumulative number of equivalent minutes at 43 °C) value for these treatments were estimated for ca. 9.6 min with the specific absorption rate (SAR) level ranging from 100 to 150 W·g−1. The as-obtained results, both cytotoxic and those related to energy calculations and SAR, may contribute to the advancement of thermal therapies, concurrently indicating that the proposed magnetic fluid hyperthermia holds a great potential for further testing in the context of medical applications.
磁流体热疗(MFH)是一种利用磁性纳米粒子在交变磁场(AMF)中的加热功能治疗癌症的有效方法。由于磁流体热疗的疗效和安全性取决于许多内在和外在因素,因此,正确的磁流体热疗设置应侧重于向癌细胞注入热能。在本研究中,我们使用人类肺癌 A549 细胞(体外)和携带人类肺癌(A549)的 NUDE Balb/c 小鼠(体内)进行了 MFH 实验。在这两个实验模型中,镁掺杂的氧化铁(III)纳米粒子包覆有 mPEG-硅烷(Mg0.1-γ-Fe2O3(mPEG-硅烷)0.5),当暴露于 AMF 时会诱导发热。我们观察到,用 Mg0.1-γ-Fe2O3(mPEG-silane)0.5(0.25 mg-mL-1)处理肺癌细胞,并在 14.4 kA-m-1 下磁化 30 分钟,结果令人满意,细胞活力降低了约 21%(体外)。该磁场强度计算出的活化能估计为 349 kJ-mol-1。通过磁共振成像(MRI)确认的体积测量和肿瘤质量评估结果显示,在瘤内注射 Mg0.1-γ-Fe2O3(mPEG-silane)0.5 纳米粒子(3 mg-mL-1)并接受 AMF(18.3 kA-m-1)30 分钟(每周四次)的人类肺癌小鼠身上,热效应非常显著。研究表明,与未接受治疗的对照组小鼠相比,接受 MFH 治疗的小鼠明显抑制了肿瘤的生长(V = 169 ± 94 mm3;p < 0.05)。这些治疗的 CEM43(43 °C 下的累积等效分钟数)值约为 9.6 分钟。9.6 分钟,比吸收率 (SAR) 为 100 至 150 W-g-1。目前获得的结果(包括细胞毒性以及与能量计算和 SAR 相关的结果)可能有助于热疗法的发展,同时表明拟议的磁流体热疗在医疗应用方面具有进一步测试的巨大潜力。
{"title":"Studies on the thermal sensitivity of lung cancer cells exposed to an alternating magnetic field and magnesium-doped maghemite nanoparticles","authors":"Malgorzata Sikorska, Grzegorz Domanski, Magdalena Bamburowicz-Klimkowska, Artur Kasprzak, Anna M. Nowicka, Monika Ruzycka-Ayoush, Ireneusz P. Grudzinski","doi":"10.1186/s12645-024-00276-0","DOIUrl":"https://doi.org/10.1186/s12645-024-00276-0","url":null,"abstract":"Magnetic fluid hyperthermia (MFH) represents a promising therapeutic strategy in cancer utilizing the heating capabilities of magnetic nanoparticles when exposed to an alternating magnetic field (AMF). Because the efficacy and safety of MFH treatments depends on numerous intrinsic and extrinsic factors, therefore, the proper MFH setups should focus on thermal energy dosed into the cancer cells. In this study, we performed MFH experiments using human lung cancer A549 cells (in vitro) and NUDE Balb/c mice bearing human lung (A549) cancer (in vivo). In these two experimental models, the heat was induced by magnesium-doped iron(III) oxide nanoparticles coated with mPEG-silane (Mg0.1-γ-Fe2O3(mPEG-silane)0.5) when exposed to an AMF. We observed that the lung cancer cells treated with Mg0.1-γ-Fe2O3(mPEG-silane)0.5 (0.25 mg·mL−1) and magnetized for 30 min at 14.4 kA·m−1 yielded a satisfactory outcome in reducing the cell viability up to ca. 21% (in vitro). The activation energy calculated for this field strength was estimated for 349 kJ·mol−1. Both volumetric measurements and tumor mass assessments confirmed by magnetic resonance imaging (MRI) showed a superior thermal effect in mice bearing human lung cancer injected intratumorally with Mg0.1-γ-Fe2O3(mPEG-silane)0.5 nanoparticles (3 mg·mL−1) and subjected to an AMF (18.3 kA·m−1) for 30 min four times at weekly intervals. Research demonstrated that mice undergoing MFH exhibited a marked suppression of tumor growth (V = 169 ± 94 mm3; p < 0.05) in comparison to the control group of untreated mice. The CEM43 (cumulative number of equivalent minutes at 43 °C) value for these treatments were estimated for ca. 9.6 min with the specific absorption rate (SAR) level ranging from 100 to 150 W·g−1. The as-obtained results, both cytotoxic and those related to energy calculations and SAR, may contribute to the advancement of thermal therapies, concurrently indicating that the proposed magnetic fluid hyperthermia holds a great potential for further testing in the context of medical applications. ","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141742301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
pH-sensitive polymeric micelles enhance the co-delivery of doxorubicin and docetaxel: an emerging modality for treating breast cancer 对 pH 值敏感的聚合物胶束可增强多柔比星和多西他赛的联合给药:一种治疗乳腺癌的新兴模式
IF 5.7 2区 工程技术 Q2 NANOSCIENCE & NANOTECHNOLOGY Pub Date : 2024-07-20 DOI: 10.1186/s12645-024-00275-1
Leila Farhoudi, Seyedeh Maryam Hosseinikhah, Amin Kazemi-Beydokhti, Leila Arabi, Seyedeh Hoda Alavizadeh, Seyedeh Alia Moosavian, Mahmoud Reza Jaafari
Designing and preparing a co-delivery system based on polymeric micelles have attracted in recent years. Co-delivery of anti-cancer agents within pH-sensitive polymeric micelles could provide superior advantages over the co-administration of free drugs, since it enables simultaneous delivery of drugs to reach an optimum synergistic dose right to the tumor. DOX was conjugated to the polymer through a hydrazine linker by Schiff’s base reaction. Then, DTX was encapsulated into the core of the polymer to the resulting DOX-Hyd-PM/DTX micelle with optimum molar ratios of 1:1 and 1:5 (DOX/DTX). The final formulations showed the desired particle size and increased release of DOX and DTX in acidic media (pH 5.5). The cytotoxicity assay of DOX-Hyd-PM/DTX indicated the highest synergistic effect on both 4T1 and TUBO cell lines over other formulations. Interestingly, in accordance with in vitro results, DOX-Hyd-PM/DTX revealed a promising anti-tumor activity in mice-bearing 4T1 breast cancer tumor with higher tumor accumulation of DOX and DTX after 24 h compared to free drugs combination. These findings point to the potential use of such smart nanodrug delivery systems in cancer treatment, where the synergistic effect of both drugs may be used to enhance therapeutic response.
近年来,设计和制备基于聚合物胶束的联合给药系统备受关注。在对 pH 值敏感的聚合物胶束中联合投放抗癌药物比联合投放游离药物更有优势,因为它能同时投放药物,以达到直达肿瘤的最佳协同剂量。通过席夫碱反应,DOX 通过肼连接物与聚合物共轭。然后,DTX 被包裹到聚合物的核心中,形成 DOX-Hyd-PM/DTX 胶束,最佳摩尔比为 1:1 和 1:5(DOX/DTX)。最终制剂显示出理想的粒度,并增加了 DOX 和 DTX 在酸性介质(pH 5.5)中的释放量。DOX-Hyd-PM/DTX的细胞毒性试验表明,与其他制剂相比,DOX-Hyd-PM/DTX对4T1和TUBO细胞株的协同效应最高。有趣的是,与体外结果一致,DOX-Hyd-PM/DTX 在小鼠 4T1 乳腺癌肿瘤中显示出良好的抗肿瘤活性,与游离药物组合相比,24 小时后 DOX 和 DTX 在肿瘤中的蓄积量更高。这些研究结果表明,这种智能纳米给药系统可用于癌症治疗,两种药物的协同作用可提高治疗效果。
{"title":"pH-sensitive polymeric micelles enhance the co-delivery of doxorubicin and docetaxel: an emerging modality for treating breast cancer","authors":"Leila Farhoudi, Seyedeh Maryam Hosseinikhah, Amin Kazemi-Beydokhti, Leila Arabi, Seyedeh Hoda Alavizadeh, Seyedeh Alia Moosavian, Mahmoud Reza Jaafari","doi":"10.1186/s12645-024-00275-1","DOIUrl":"https://doi.org/10.1186/s12645-024-00275-1","url":null,"abstract":"Designing and preparing a co-delivery system based on polymeric micelles have attracted in recent years. Co-delivery of anti-cancer agents within pH-sensitive polymeric micelles could provide superior advantages over the co-administration of free drugs, since it enables simultaneous delivery of drugs to reach an optimum synergistic dose right to the tumor. DOX was conjugated to the polymer through a hydrazine linker by Schiff’s base reaction. Then, DTX was encapsulated into the core of the polymer to the resulting DOX-Hyd-PM/DTX micelle with optimum molar ratios of 1:1 and 1:5 (DOX/DTX). The final formulations showed the desired particle size and increased release of DOX and DTX in acidic media (pH 5.5). The cytotoxicity assay of DOX-Hyd-PM/DTX indicated the highest synergistic effect on both 4T1 and TUBO cell lines over other formulations. Interestingly, in accordance with in vitro results, DOX-Hyd-PM/DTX revealed a promising anti-tumor activity in mice-bearing 4T1 breast cancer tumor with higher tumor accumulation of DOX and DTX after 24 h compared to free drugs combination. These findings point to the potential use of such smart nanodrug delivery systems in cancer treatment, where the synergistic effect of both drugs may be used to enhance therapeutic response. ","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141742304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resveratrol-based nano-formulations as an emerging therapeutic strategy for ovarian carcinoma: autophagy stimulation and SIRT-1/Beclin/MMP-9/P53/AKT signaling 基于白藜芦醇的纳米制剂作为卵巢癌的新兴治疗策略:自噬刺激和 SIRT-1/Beclin/MMP-9/P53/AKT 信号传导
IF 4.5 2区 工程技术 Q2 NANOSCIENCE & NANOTECHNOLOGY Pub Date : 2024-07-15 DOI: 10.1186/s12645-024-00274-2
Mai O. Kadry
{"title":"Resveratrol-based nano-formulations as an emerging therapeutic strategy for ovarian carcinoma: autophagy stimulation and SIRT-1/Beclin/MMP-9/P53/AKT signaling","authors":"Mai O. Kadry","doi":"10.1186/s12645-024-00274-2","DOIUrl":"https://doi.org/10.1186/s12645-024-00274-2","url":null,"abstract":"","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141644885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extracellular vesicle miRNAs for predicting the efficacy of late-line treatment with anlotinib in patients with lung adenocarcinoma 预测肺腺癌患者接受安罗替尼晚线治疗疗效的细胞外囊泡miRNA
IF 5.7 2区 工程技术 Q2 NANOSCIENCE & NANOTECHNOLOGY Pub Date : 2024-07-02 DOI: 10.1186/s12645-024-00273-3
Aimi Huang, Fuchuang Zhang, Jiyang Zhang, Xiaoya Xu, Zhikuan Li, Sheng Chen, Baoning Nian, Dadong Zhang, Baohui Han, Aiqin Gu, Weimin Wang
Anlotinib is a targeted therapy indicated for some malignancies, including advanced non-small cell lung cancer (NSCLC). However, noninvasive biomarkers for identifying patients who will benefit from this disease remain lacking. Here, we investigated the potential of small extracellular vesicle (sEV) microRNAs (miRNAs) as predictive biomarkers for anlotinib efficacy. A total of 20 advanced NSCLC patients were enrolled. Patients were classified as having stable disease (SD) or progressive disease (PD) after the initial efficacy assessment. Seven differentially expressed miRNAs (DEMs) were identified. Among them, miR-941 was significantly upregulated in the PD group, while the others were downregulated. Furthermore, these six downregulated miRNAs (miR-30a-3p, miR-150-5p, miR-122-5p, miR-10b-5p, miR-92a-3p, and miR-150-3p) were more pronounced in nonsmoking patients. It was found that sEV miRNAs have the potential to predict the benefit of anlotinib.
安罗替尼是一种适用于包括晚期非小细胞肺癌(NSCLC)在内的某些恶性肿瘤的靶向疗法。然而,目前仍缺乏非侵入性生物标志物来识别将从这种疾病中获益的患者。在这里,我们研究了细胞外小泡(sEV)微RNA(miRNA)作为安罗替尼疗效预测生物标志物的潜力。共招募了20名晚期NSCLC患者。初步疗效评估后,患者被分为病情稳定(SD)和病情进展(PD)两类。研究发现了七种差异表达的 miRNA(DEMs)。其中,miR-941 在进展期组显著上调,而其他则下调。此外,这六个下调的 miRNA(miR-30a-3p、miR-150-5p、miR-122-5p、miR-10b-5p、miR-92a-3p 和 miR-150-3p)在非吸烟患者中更为明显。研究发现,sEV miRNAs有可能预测安罗替尼的疗效。
{"title":"Extracellular vesicle miRNAs for predicting the efficacy of late-line treatment with anlotinib in patients with lung adenocarcinoma","authors":"Aimi Huang, Fuchuang Zhang, Jiyang Zhang, Xiaoya Xu, Zhikuan Li, Sheng Chen, Baoning Nian, Dadong Zhang, Baohui Han, Aiqin Gu, Weimin Wang","doi":"10.1186/s12645-024-00273-3","DOIUrl":"https://doi.org/10.1186/s12645-024-00273-3","url":null,"abstract":"Anlotinib is a targeted therapy indicated for some malignancies, including advanced non-small cell lung cancer (NSCLC). However, noninvasive biomarkers for identifying patients who will benefit from this disease remain lacking. Here, we investigated the potential of small extracellular vesicle (sEV) microRNAs (miRNAs) as predictive biomarkers for anlotinib efficacy. A total of 20 advanced NSCLC patients were enrolled. Patients were classified as having stable disease (SD) or progressive disease (PD) after the initial efficacy assessment. Seven differentially expressed miRNAs (DEMs) were identified. Among them, miR-941 was significantly upregulated in the PD group, while the others were downregulated. Furthermore, these six downregulated miRNAs (miR-30a-3p, miR-150-5p, miR-122-5p, miR-10b-5p, miR-92a-3p, and miR-150-3p) were more pronounced in nonsmoking patients. It was found that sEV miRNAs have the potential to predict the benefit of anlotinib.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141510326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biocompatible PLGA-PCL nanobeads for efficient delivery of curcumin to lung cancer 生物相容性 PLGA-PCL 纳米吸附剂用于向肺癌患者高效递送姜黄素
IF 5.7 2区 工程技术 Q2 NANOSCIENCE & NANOTECHNOLOGY Pub Date : 2024-06-24 DOI: 10.1186/s12645-024-00272-4
Sheida Sadeghi, Javad Mohammadnejad, Akram Eidi, Hanieh Jafary
Lung cancer has been mentioned as the first and second most prevalent cancer among males and females worldwide, respectively since conventional approaches do not have enough efficiency in its suppression. Therefore, a biocompatible and efficient polylactic-co-glycolic acid (PLGA: P)- poly-ε-caprolactone (PCL: P) copolymer was fabricated for delivery of relatively insoluble curcumin (Cur) to A549 lung cancer cells. Next, the physicochemical aspects of the synthesized nanobeads were characterized by applying analytical sets, including FT-IR, DLS, TEM, and TGA as nano-metric size (20–45 nm) and 1.29% of Cur entrapment efficiency were determined for P-P-Cur nano-beads. Thereafter, a controlled (5% within 2 h at pH 7.4) and pH-sensitive (nearly 50% within 4 h at pH 5.0) drug release manner was observed for P-P-Cur nanobeads. Thereafter, biomedical assays were conducted for the cancer suppression ability of nanobeads. 41% cell viability after 24 h of treatment with 200 nM concentration and 7.55% cell cycle arrest at 5 h of post-treatment with 100 nM (IC50) concentration were attained for P-P-Cur. Also, 7-fold increase and 2-fold decrease in the expressions of Caspase-9 (apoptotic gene) and Bcl2 (anti-apoptotic gene) were observed which have further approved the cancer inhibition potency of the P-P-Cur sample. The cellular uptake results indicated 91% internalization in A549 cells while it was less than 1% for the pure Cur. These data have demonstrated that P-P-Cur can use as a biocompatible drug delivery system for Cur and treatment of lung cancer.
肺癌在全球男性和女性癌症发病率中分别位居第一和第二位,而传统方法对肺癌的抑制效果不佳。因此,研究人员制备了一种生物相容性好且高效的聚乳酸-聚甘醇酸(PLGA:P)-聚ε-己内酯(PCL:P)共聚物,用于向 A549 肺癌细胞递送相对不溶性的姜黄素(Cur)。接着,应用 FT-IR、DLS、TEM 和 TGA 等分析装置对合成的纳米珠的理化性质进行了表征,确定了 P-P-Cur 纳米珠的纳米尺寸(20-45 nm)和 1.29% 的姜黄素包载效率。此后,观察到 P-P-Cur 纳米珠的药物释放方式具有可控性(pH 值为 7.4 时,2 小时内释放 5%)和 pH 值敏感性(pH 值为 5.0 时,4 小时内释放近 50%)。随后,对纳米珠的抑癌能力进行了生物医学实验。在使用 200 nM 浓度的 P-P-Cur 处理 24 小时后,细胞存活率达到 41%;在使用 100 nM(IC50)浓度的 P-P-Cur 处理 5 小时后,细胞周期停滞率达到 7.55%。此外,还观察到 Caspase-9(凋亡基因)和 Bcl2(抗凋亡基因)的表达量分别增加了 7 倍和减少了 2 倍,这进一步证实了 P-P-Cur 样品的抑癌功效。细胞吸收结果表明,A549 细胞的内化率为 91%,而纯 Cur 的内化率不到 1%。这些数据表明,P-P-Cur 可作为一种生物相容性药物递送系统,用于 Cur 和肺癌的治疗。
{"title":"Biocompatible PLGA-PCL nanobeads for efficient delivery of curcumin to lung cancer","authors":"Sheida Sadeghi, Javad Mohammadnejad, Akram Eidi, Hanieh Jafary","doi":"10.1186/s12645-024-00272-4","DOIUrl":"https://doi.org/10.1186/s12645-024-00272-4","url":null,"abstract":"Lung cancer has been mentioned as the first and second most prevalent cancer among males and females worldwide, respectively since conventional approaches do not have enough efficiency in its suppression. Therefore, a biocompatible and efficient polylactic-co-glycolic acid (PLGA: P)- poly-ε-caprolactone (PCL: P) copolymer was fabricated for delivery of relatively insoluble curcumin (Cur) to A549 lung cancer cells. Next, the physicochemical aspects of the synthesized nanobeads were characterized by applying analytical sets, including FT-IR, DLS, TEM, and TGA as nano-metric size (20–45 nm) and 1.29% of Cur entrapment efficiency were determined for P-P-Cur nano-beads. Thereafter, a controlled (5% within 2 h at pH 7.4) and pH-sensitive (nearly 50% within 4 h at pH 5.0) drug release manner was observed for P-P-Cur nanobeads. Thereafter, biomedical assays were conducted for the cancer suppression ability of nanobeads. 41% cell viability after 24 h of treatment with 200 nM concentration and 7.55% cell cycle arrest at 5 h of post-treatment with 100 nM (IC50) concentration were attained for P-P-Cur. Also, 7-fold increase and 2-fold decrease in the expressions of Caspase-9 (apoptotic gene) and Bcl2 (anti-apoptotic gene) were observed which have further approved the cancer inhibition potency of the P-P-Cur sample. The cellular uptake results indicated 91% internalization in A549 cells while it was less than 1% for the pure Cur. These data have demonstrated that P-P-Cur can use as a biocompatible drug delivery system for Cur and treatment of lung cancer.","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141530125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Delivery of letrozole-encapsulated niosomes via a 3D bioprinting gelatin–alginate scaffold for potential breast cancer treatment 通过三维生物打印明胶-海藻酸盐支架递送来曲唑胶囊剂,用于潜在的乳腺癌治疗
IF 5.7 2区 工程技术 Q1 Chemistry Pub Date : 2024-06-15 DOI: 10.1186/s12645-024-00271-5
Neda Mahdizadeh, Mahtab Khorshid Shabestari, F. Tafvizi, Parvin Khodarahmi
{"title":"Delivery of letrozole-encapsulated niosomes via a 3D bioprinting gelatin–alginate scaffold for potential breast cancer treatment","authors":"Neda Mahdizadeh, Mahtab Khorshid Shabestari, F. Tafvizi, Parvin Khodarahmi","doi":"10.1186/s12645-024-00271-5","DOIUrl":"https://doi.org/10.1186/s12645-024-00271-5","url":null,"abstract":"","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141336285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Carboxymethyl-sagocellulose-stabilized Fe3O4 nanoparticles with 5-fuorouracil as photothermal agents for tumor ablation 更正:含有 5-氟尿嘧啶的羧甲基纤维素稳定的 Fe3O4 纳米粒子作为肿瘤消融的光热剂
IF 5.7 2区 工程技术 Q1 Chemistry Pub Date : 2024-06-14 DOI: 10.1186/s12645-024-00263-5
Anand Kumar Veeramachineni, T. Sathasivam, R. Paramasivam, Saravanan Muniyandy, Shafii Bin Khamis, Yau Yan Lim, J. Pushpamalar
{"title":"Correction: Carboxymethyl-sagocellulose-stabilized Fe3O4 nanoparticles with 5-fuorouracil as photothermal agents for tumor ablation","authors":"Anand Kumar Veeramachineni, T. Sathasivam, R. Paramasivam, Saravanan Muniyandy, Shafii Bin Khamis, Yau Yan Lim, J. Pushpamalar","doi":"10.1186/s12645-024-00263-5","DOIUrl":"https://doi.org/10.1186/s12645-024-00263-5","url":null,"abstract":"","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141344393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: HepG2 exosomes coated luteolin nanoparticles remodeling hepatic stellate cells and combination with sorafenib for the treatment of hepatocellular carcinoma 更正:HepG2外泌体包被木犀草素纳米颗粒重塑肝星状细胞并与索拉非尼联合治疗肝细胞癌
IF 5.7 2区 工程技术 Q1 Chemistry Pub Date : 2024-06-14 DOI: 10.1186/s12645-024-00268-0
Shengjie Ye, Xier Pan, Lei Zhang, Yanlong Hong, Kaili Hu
{"title":"Correction: HepG2 exosomes coated luteolin nanoparticles remodeling hepatic stellate cells and combination with sorafenib for the treatment of hepatocellular carcinoma","authors":"Shengjie Ye, Xier Pan, Lei Zhang, Yanlong Hong, Kaili Hu","doi":"10.1186/s12645-024-00268-0","DOIUrl":"https://doi.org/10.1186/s12645-024-00268-0","url":null,"abstract":"","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141338874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Nanotechnology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1